Publications
1,347
Citations
64,945
Est. group size
~74
Recurring co-author estimate
Active years
32
Publishing since 1994
John C. Byrd's research focuses on blood cancers, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), with an emphasis on developing and testing new drugs such as BTK inhibitors, BCL-2 inhibitors, and JAK2 inhibitors. His work spans laboratory studies of cancer cell biology and genetics as well as clinical trials evaluating new treatment combinations and risk-stratification tools for patients. He also studies related conditions like Richter transformation and graft-versus-host disease following stem cell transplants.
Publication output has fluctuated over the past decade, with a notable spike in 2023 followed by a sharp decline in 2024-2025, though this recent drop may partly reflect incomplete indexing of the most recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
Blood · 2025
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology · 2025
- Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML
Blood Neoplasia · 2025
- Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)
Leukemia · 2025
- Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era
American Journal of Hematology · 2025
- Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor
Blood · 2025
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
Transplantation and Cellular Therapy · 2025
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
The Journal of Immunology · 2025
- Systematic molecular profiling to identify determinants of response to ibrutinib
Blood · 2025
- ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases
Blood · 2025
- Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma
Blood · 2025
- Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib
Blood · 2024
- Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
Journal of Clinical Oncology · 2024
- Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Blood Advances · 2024
- Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
Blood Advances · 2024
- Blood×209
- Journal of Clinical Oncology×35
- Leukemia×28
- Blood Advances×25
- Cancer Research×21
- Amy S. Ruppert
Medicine · The Ohio State University
- Kyoko Yamaguchi
Medicine · The Ohio State University
- Cecelia Miller
Medicine · The Ohio State University
- Daniel Jones
Medicine · The Ohio State University
- Michael R. Grever
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile